Tecalcet hydrochloride | KRN-568; NPS-R-568; R-568 | 148717-54-8 | 177172-49-5 | calcium channel agonist

MedKoo Cat#: 328014 | Name: Tecalcet HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tecalcet, also known as KRN-568; NPS-R-568; R-568, is a calcium channel agonist potentially for the treatment of hyperparathyroidism, postmenopausal. NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism.NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. NPS R-568 halts or reverses osteitis fibrosa in uremic rats.

Chemical Structure

Tecalcet HCl

CAS#177172-49-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 328014

Name: Tecalcet HCl

CAS#: 177172-49-5 (HCl)

Chemical Formula: C18H23Cl2NO

Exact Mass:

Molecular Weight: 340.29

Elemental Analysis: C, 63.53; H, 6.81; Cl, 20.84; N, 4.12; O, 4.70

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 250.00
20mg	USD 450.00
50mg	USD 950.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

148717-54-8 (free base) 177172-49-5 (HCl)

Synonym

Tecalcet hydrochloride; Tecalcet HCl; KRN-568; NPS-R-568; R-568; KRN568; NPS-R568; R568. Norcalcin

IUPAC/Chemical Name

3-(2-Chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)propan-1-amine hydrochloride

InChi Key

YJXUXANREVNZLH-PFEQFJNWSA-N

InChi Code

InChI=1S/C18H22ClNO.ClH/c1-14(16-8-5-10-17(13-16)21-2)20-12-6-9-15-7-3-4-11-18(15)19;/h3-5,7-8,10-11,13-14,20H,6,9,12H2,1-2H3;1H/t14-;/m1./s1

SMILES Code

C[C@@H](NCCCC1=CC=CC=C1Cl)C2=CC=CC(OC)=C2.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 148717-54-8 (Tecalcet) 177172-49-5 (Tecalcet hydrochloride)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 340.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Nakamura A, Hotsubo T, Kobayashi K, Mochizuki H, Ishizu K, Tajima T. Loss-of-function and gain-of-function mutations of calcium-sensing receptor: functional analysis and the effect of allosteric modulators NPS R-568 and NPS 2143. J Clin Endocrinol Metab. 2013 Oct;98(10):E1692-701. doi: 10.1210/jc.2013-1974. Epub 2013 Aug 21. PubMed PMID: 23966241. 2: Rus R, Haag C, Bumke-Vogt C, Bähr V, Mayr B, Möhlig M, Schulze E, Frank-Raue K, Raue F, Schöfl C. Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors. J Clin Endocrinol Metab. 2008 Dec;93(12):4797-803. doi: 10.1210/jc.2008-1076. Epub 2008 Sep 16. PubMed PMID: 18796518. 3: Fernández I, Valdivia V, Khiar N. N-isopropylsulfinylimines as useful intermediates in the synthesis of chiral amines: expeditive asymmetric synthesis of the calcimimetic (+)-NPS R-568. J Org Chem. 2008 Jan 18;73(2):745-8. Epub 2007 Dec 23. PubMed PMID: 18154349. 4: Rybczyńska A, Boblewski K, Lehmann A, Orlewska C, Foks H. Pharmacological activity of calcimimetic NPS R-568 administered intravenously in rats: dose dependency. Pharmacol Rep. 2006 Jul-Aug;58(4):533-9. PubMed PMID: 16963800. 5: Rybczyńska A, Boblewski K, Lehmann A, Orlewska C, Foks H, Drewnowska K, Hoppe A. Calcimimetic NPS R-568 induces hypotensive effect in spontaneously hypertensive rats. Am J Hypertens. 2005 Mar;18(3):364-71. PubMed PMID: 15797655. 6: Miller MA, Fox J. Daily transient decreases in plasma parathyroid hormone levels induced by the calcimimetic NPS R-568 slows the rate of bone loss but does not increase bone mass in ovariectomized rats. Bone. 2000 Oct;27(4):511-9. PubMed PMID: 11033446. 7: Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int. 2000 Jan;57(1):50-8. PubMed PMID: 10620187. 8: Fox J, Lowe SH, Conklin RL, Nemeth EF. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine. 1999 Apr;10(2):97-103. PubMed PMID: 10451217. 9: Fox J, Lowe SH, Conklin RL, Petty BA, Nemeth EF. Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. J Pharmacol Exp Ther. 1999 Aug;290(2):480-6. PubMed PMID: 10411553. 10: Fox J, Lowe SH, Petty BA, Nemeth EF. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther. 1999 Aug;290(2):473-9. PubMed PMID: 10411552. 11: Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. 1998 Feb;53(2):448-53. PubMed PMID: 9461105. 12: Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest. 1997 Dec 15;100(12):2977-83. PubMed PMID: 9399943; PubMed Central PMCID: PMC508509.